BCRX
BIOCRYST PHARMACEUTICALS INC · Healthcare · Market cap $2.1B
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Sep 2, 2026
McKee Amy E
BIOCRYST PHARMACEUTICALS INC (BCRX) has 45 SEC Form 4 filings (61 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Sep 2, 2026.
Inside the rolling window, 4 insiders at BIOCRYST PHARMACEUTICALS INC reported no open-market purchases and 10 open-market sales totaling $4.1M. The most active filer is Chief Legal Officer Barnes Alane P with 7 filings. Insiders have net sold $2.6M over the trailing 6 months. The most recent open-market filing is a sale of 11,180 shares by Director McKee Amy E, dated May 18, 2026, worth $100K.
- Industry:Biotechnology
- CEO:Charles K. Gayer
- Employees:435
- HQ:Durham, NC, US
- IPO:1994-03-04
| Source | |||||||
|---|---|---|---|---|---|---|---|
McKee Amy EFirst filing | Director | Sale | 11,180 | $100K | May 19 | -5.5% | SEC ↗ |
| Chief Legal Officer | Sale | 62,500 | $596K | May 15 | -8.1% | SEC ↗ | |
HEGGIE THERESAFirst filing | Director | Sale | 49,933 | $505K | Mar 24 | -14.2% | SEC ↗ |
| Chief Legal Officer | Sale | 150,000 | $1.4M | Mar 18 | -9.5% | SEC ↗ | |
| Chief Legal Officer | Sale | 21,773 | $167K | Dec 23 | +10.1% | SEC ↗ | |
| Chief Legal Officer | Sale | 21,210 | $162K | Dec 16 | +11.0% | SEC ↗ | |
Barnes Alane PFirst filing | Chief Legal Officer | Sale | 91,004 | $647K | Dec 3 | +5.6% | SEC ↗ |
Barnes Alane PFirst filing | Chief Legal Officer | Sale | 50,906 | $367K | Dec 3 | +5.6% | SEC ↗ |
Barnes Alane PFirst filing | Chief Legal Officer | Sale | 19,770 | $151K | Dec 3 | +5.6% | SEC ↗ |
SANDERS MACHELLEFirst filing | Director | Sale | 9,600 | $69K | Nov 17 | +17.9% | SEC ↗ |
Congress trading BCRX 5 all-time
- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-07-10
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-07-09
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002025-11-13
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002023-10-16
- DRep. Josh S. GottheimerSale$1,001 - $15,0002023-09-15
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does BCRX have?
BIOCRYST PHARMACEUTICALS INC (BCRX) has 45 SEC Form 4 filings (61 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Sep 2, 2026.
When was the most recent SEC Form 4 filing for BCRX?
The most recent Form 4 filing for BCRX on Tracefour is dated Sep 2, 2026.
Who is the most active insider at BCRX?
The most active SEC Form 4 filer at BCRX in the rolling window is Chief Legal Officer Barnes Alane P, with 7 filings.
What is the net insider flow at BCRX over the last 6 months?
Over the trailing 180 days, insiders at BCRX have net sold $2.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at BCRX in the current window?
Inside the rolling window, insiders at BCRX bought $0 and sold $4.1M based on SEC Form 4 filings.
Can I get alerts for BCRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at BIOCRYST PHARMACEUTICALS INC (BCRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
BIOCRYST PHARMACEUTICALS INC is in the Healthcare sector.